Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
Key Highlights
- ➤Evotec appoints Dr. Joanna Holbrook chief scientific officer effective November 1, 2026
- ➤Holbrook joins with more than 25 years of pharma, biotech, and academic experience
- ➤Holbrook will lead Evotec’s global scientific strategy and drive differentiation across its platforms
- ➤Holbrook most recently led cardiovascular, renal, and hepatic disease therapy areas at Novo Nordisk
Expert Statements
Dr. Christian Wojczewski, Chief Executive Officer of Evotec
“Joanna has a keen understanding of how data, AI and new technologies are transforming drug discovery and development today. She combines this forward-looking perspective with deep scientific expertise and a strong focus on generating robust, actionable results. I look forward to working with her as we continue to strengthen Evotec's position as a leading partner for any organization that strives to bring new, groundbreaking medicines to market.”
Dr. Joanna Holbrook, Incoming Chief Scientific Officer of Evotec
“Evotec has exceptional breadth of scientific expertise and capabilities spanning drug discovery, drug development and manufacturing. I am excited by the opportunity to work across the business to strengthen our scientific differentiation, build integrated solutions to the most important challenges in drug discovery, and develop new capabilities that are unique to Evotec.”
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board PR Newswire
* Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation * Brings more than 25 years of global experience in pharma, biotechnology and academia HAMBURG, Germany, Oct. 15, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to the challenges of drug discovery and advancing programs toward the clinic. Her experience spans multi-modal 'omics, data science, novel therapeutic modalities and precision medicine, complemented by experience in commercializing innovative technologies, shaping drug discovery partnerships and leading therapeutic research portfolios. At Evotec, Dr. Holbrook will draw on recent scientific advances to help customers and partners discover and develop new medicines faster and with a higher probability of success.
Get started
Create a free account to read the full story.